Erschienen in:
28.07.2020 | ASO Author Reflections
ASO Author Reflections: Time for a Paradigm Shift in “Hormone Receptor Positive” Invasive Breast Cancer?
verfasst von:
Christine Dauphine, MD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2020
Einloggen, um Zugang zu erhalten
Excerpt
The Current National Comprehensive Cancer Network
1 and American Society of Clinical Oncology
2 clinical practice guidelines outline treatment algorithms for “hormone receptor positive” human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancers, not specifically accounting for the estrogen receptor (ER) and progesterone receptor (PR) status individually. This is largely due to the fact that clinical trials have routinely grouped cancers as “hormone receptor positive” regardless of whether one or both ER and PR stain positive in at least 1% of cells on immunohistochemical evaluation of tissue samples. …